Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC boost for China Pharma

This article was originally published in The Tan Sheet

Executive Summary

China Pharma Holdings' 2008 net income grows 39 percent to $17.8 million due to a 76.6 percent sales increase of OTC cold and flu product PuSen OK (naproxen and pseudophedrine), the only generic version of Bayer's Aleve-D in China. Located in Haikou, the capital of the Hainan province, China Pharma markets 18 products treating infectious diseases, flu/cold and cardiovascular disease and makes nutritional supplements and traditional Chinese medicine, according to a March 17 release. The company is developing generic drugs for off-patent blockbuster drugs but is shifting to an innovative biopharmaceutical enterprise through the products in its pipeline
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS102755

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel